Trials / Completed
CompletedNCT00109057
An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin (bevacizumab) |
Timeline
- Start date
- 1998-02-01
- Completion
- 2004-02-01
- First posted
- 2005-04-25
- Last updated
- 2013-06-21
Source: ClinicalTrials.gov record NCT00109057. Inclusion in this directory is not an endorsement.